Triple-negative breast cancer influences a mixed M1/M2 macrophage phenotype associated with tumor aggressiveness.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
12
2021
accepted:
02
08
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
17
8
2022
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is characterized by excessive accumulation of tumor-infiltrating immune cells, including tumor-associated macrophages (TAMs). TAMs consist of a heterogeneous population with high plasticity and are associated with tumor aggressiveness and poor prognosis. Moreover, breast cancer cells can secrete factors that influence TAM polarization. Therefore, this study aimed to evaluate the crosstalk between cancer cells and macrophages in the context of TNBC. Cytokine-polarized M2 macrophage were used as control. Distinct from the classical M2 macrophage, TAMs generated from TNBC-conditioned media upregulated both M1- and M2-associated genes, and secreted both the anti-inflammatory cytokine interleukin IL-10 and the proinflammatory cytokine IL-6 and tumor necrosis factor- α. Theses TNBC-induced TAMs exert aggressive behavior of TNBC cells. Consistently, TCGA and MTABRIC analyses of human breast cancer revealed upregulation of M1- associated genes in TNBC comparing with non-TNBC. Among these M1-associated genes, CXCL10 and IL1B were revealed to be independent prognostic factors for disease progression. In conclusion, TNBC cells induce macrophage polarization with a mixture of M1 and M2 phenotypes. These cancer-induced TAMs further enhance tumor cell growth and aggressiveness.
Identifiants
pubmed: 35960749
doi: 10.1371/journal.pone.0273044
pii: PONE-D-21-39755
pmc: PMC9374254
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0273044Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Inflamm Res. 2007 Jan;56(1):45-50
pubmed: 17334670
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Oncotarget. 2017 Jul 21;8(36):60210-60222
pubmed: 28947965
J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92
pubmed: 21069385
Cancer Res. 2013 Jun 1;73(11):3470-80
pubmed: 23633491
Cancer Immunol Immunother. 2017 Dec;66(12):1597-1608
pubmed: 28828629
Cell Immunol. 2014 Jul;290(1):107-15
pubmed: 24960291
Biochim Biophys Acta Rev Cancer. 2018 Jan;1869(1):78-84
pubmed: 29126881
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Sci Rep. 2015 Mar 17;5:9188
pubmed: 25776849
J Invest Dermatol. 2017 Feb;137(2):e11-e16
pubmed: 28110712
Oncotarget. 2017 May 2;8(18):30576-30586
pubmed: 28427165
BMC Cancer. 2010 Jul 17;10:375
pubmed: 20637124
Chin J Cancer. 2011 Apr;30(4):280-6
pubmed: 21439250
J Transl Med. 2014 Sep 24;12:267
pubmed: 25245466
Am J Cancer Res. 2019 Oct 01;9(10):2194-2208
pubmed: 31720082
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Oncol Lett. 2021 May;21(5):383
pubmed: 33777206
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842422
Cancer Res. 2015 Nov 1;75(21):4483-93
pubmed: 26432403
Rocz Akad Med Bialymst. 2003;48:82-4
pubmed: 14737948
PLoS One. 2013 Oct 04;8(10):e76379
pubmed: 24124553
Onco Targets Ther. 2019 Apr 18;12:3051-3063
pubmed: 31114248
Pigment Cell Melanoma Res. 2012 Jul;25(4):493-505
pubmed: 22498258
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Hum Immunol. 2009 Mar;70(3):151-8
pubmed: 19272324
BMC Cancer. 2015 Aug 08;15:577
pubmed: 26253167
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17582-7
pubmed: 25422452
Biomed Pharmacother. 2018 Dec;108:1415-1424
pubmed: 30372844
Front Cell Dev Biol. 2016 Mar 30;4:21
pubmed: 27066479
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17253-8
pubmed: 24101477
Lung Cancer. 2018 May;119:25-35
pubmed: 29656749
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Oncotarget. 2017 Feb 7;8(6):9739-9751
pubmed: 28039457
Cell Immunol. 2018 Oct;332:58-76
pubmed: 30077333
J Leukoc Biol. 2009 Nov;86(5):1065-73
pubmed: 19741157
Genes Dev. 2010 Feb 1;24(3):241-55
pubmed: 20080943
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Medicine (Baltimore). 2016 Feb;95(6):e2636
pubmed: 26871785
Int J Oncol. 2017 Jul;51(1):25-38
pubmed: 28534943
J Biochem Mol Toxicol. 2018 Mar;32(3):e22039
pubmed: 29341321
J Immunol. 2006 Apr 15;176(8):5023-32
pubmed: 16585599
Mol Cancer Res. 2012 Jun;10(6):727-38
pubmed: 22532586
J Immunol Res. 2018 Jan 14;2018:8917804
pubmed: 29507865
J Immunol. 2005 Jul 1;175(1):342-9
pubmed: 15972667
Mol Cancer. 2019 Mar 18;18(1):42
pubmed: 30885232
Front Oncol. 2020 Oct 22;10:566511
pubmed: 33194645
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
Data Brief. 2019 Nov 14;28:104798
pubmed: 31828190
Nat Rev Immunol. 2005 Dec;5(12):953-64
pubmed: 16322748
Chin J Cancer Res. 2017 Jun;29(3):237-252
pubmed: 28729775
Oncotarget. 2020 Dec 29;11(52):4845-4846
pubmed: 33447352
Breast Cancer Res Treat. 2009 Nov;118(1):131-7
pubmed: 19189211
Tumour Biol. 2018 Sep;40(9):1010428318797880
pubmed: 30183516
Breast Cancer Res. 2015 Aug 05;17:101
pubmed: 26243145